文献速递瓣膜外科

Mitroflow主动脉心包生物瓣长期耐久性有限:800余例回顾性分析

Long-term results of the Mitroflow aortic pericardial bioprosthesis in over 800 patients: limited durability and mechanisms of dysfunction.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

结果显示5年和9年免于结构性瓣膜衰败率分别为95.4%和67.9%,衰败以狭窄为主,年龄增长为保护因素,长期耐久性有限。

要点

  • Mitroflow LA/LXA模型长期耐久性有限,9年免于SVD仅67.9%。
  • SVD以狭窄为主,年龄增长是SVD的保护因素。
  • 9年时10.0%患者带衰败瓣膜生存,7.1%死于瓣膜衰败后。

核心结论

  • Mitroflow LA/LXA模型长期耐久性有限,衰败以狭窄为主,患者年龄对SVD发展有重要作用。

主要发现

  • 5年和9年免于SVD率分别为95.4%和67.9%,按瓣膜型号(P=0.87)和尺寸(P=0.70)分层无差异。
  • 多变量分析中,年龄增长是SVD的保护因素(HR=0.94,P<0.001)。
  • SVD患者中20例(38.4%)接受再次主动脉瓣置换。
  • 5年和9年生存率分别为64.5%和43.1%;9年时10.0%患者带衰败瓣膜生存,7.1%死于衰败后。

关键数值与推荐

  • 5年免于SVD率95.4%,9年67.9%。
  • 年龄增长保护SVD的HR=0.94(P<0.001)。
  • 5年生存率64.5%,9年43.1%。

临床怎么用

  • 对于接受Mitroflow LA/LXA生物瓣置换的患者,应加强长期随访监测SVD,尤其年轻患者。

局限性

  • 回顾性单中心设计,仅纳入随访完整患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Mitroflow aortic pericardial bioprosthesis was widely employed in the past. However, some authors have recently reported early structural valve deterioration (SVD) of the Mitroflow LA/LXA model. Thus, we reviewed our experience with the Mitroflow bioprosthesis and studied the risk factors for SVD and mortality. METHODS: Records of patients who underwent aortic valve replacement with a Mitroflow bioprosthesis between November 2005 and January 2015 were retrospectively evaluated with Kaplan-Meier, Cox-regression and multistate analysis. Only patients with a complete clinical follow-up were included in the study. Average follow-up was 45 months and ended on 1 April 2016. RESULTS: Between November 2005 and January 2015, among the 916 patients undergoing aortic valve replacement with the Mitroflow prosthesis at our Institution, the 832 (90.8%) patients with follow-up information were included into the study. Fifty-two (6.2%) patients developed SVD (stenosis, n = 38; regurgitation, n = 7; mixed, n = 7). Freedom from SVD was 95.4% and 67.9%, at 5 and 9 years, respectively, without differences after stratification according to the prosthesis model ( P = 0.87) and prosthesis size ( P = 0.70). At the multivariable analysis, increasing age was identified as a protective factor against SVD (hazard ratio = 0.94, P < 0.001). Twenty (38.4%) patients with SVD underwent redo aortic valve replacement. At 5 and 9 years, survival was 64.5% and 43.1%, repectively. According to the multistate analysis, the fraction of patients living with degenerated valves at 9 years was 10.0%; 7.1% died following degeneration. CONCLUSIONS: The LA/LXA Mitroflow model showed limited long-term durability. Degenerated prostheses showed more stenosis than regurgitation. Patient age played an important role in the development of SVD.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Ius F, Schulz J, Roumieh M, et al. Long-term results of the Mitroflow aortic pericardial bioprosthesis in over 800 patients: limited durability and mechanisms of dysfunction. Eur J Cardiothorac Surg. 2017. PMID: 28838100. doi:10.1093/ejcts/ezx161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。